NCT05239546View on ClinicalTrials.gov

Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 24, 2023

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2029

Conditions
Colon CancerdMMR Colorectal Cancer
Interventions
DRUG

Dostarlimab

Participants will receive Dostarlimab 500 mg IV every 3 weeks for 6 cycles followed by 1000 mg every 6 weeks for 8 cycles until 1.5 years

Trial Locations (1)

52242

RECRUITING

University of Iowa Hospitals & Clinics, Iowa City

All Listed Sponsors
lead

University of Iowa

OTHER